Ohio is currently home to 3201 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Developing E-liquid Product Standards (Sweet Spot Study)
NCT05864586
Recruiting
The Sweet Spot Study aims to evaluate the effect of e-liquids with nicotine varying in freebase (FB) levels and concentrations on the appeal of electronic cigarettes (ECs) in young adult EC users with minimal/no history of smoking and older adult smokers.
Gender:
ALL
Ages:
Between 21 years and 50 years
Trial Updated:
06/20/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Nicotine, Nicotine Vaping, E-cigarette Use
Register for Updates
BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
NCT05161429
Recruiting
An observational study of electronic patient data to compare diabetes medications and to determine which ones offer the best balance of risks and benefits.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
06/16/2023
Locations: Greater Plains Collaborative, Beachwood, Ohio
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Endoscopic Ultrasound-guided Radiofrequency Ablation of Pancreatic Cysts (ERASE)
NCT05916846
Recruiting
A single-center study to determine the safety and efficacy of EUS-guided radiofrequency ablation (RFA) of pancreatic cystic neoplasms (PCNs). Patients will be recruited sequentially to undergo RFA followed by standard surveillance. The study will recruit patients with pancreatic cystic lesions (PCLs) who are at high risk for surgical resection. Patients enrolled in the study will be followed up for 3-years after EUS-guided RFA.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Pancreatic Cyst, Radiofrequency Ablation
Register for Updates
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
NCT05268666
Recruiting
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2023
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Curvafix® Intramedullary System for Fixation of Pelvic and Acetabular Fractures, A Post Market Evaluation
NCT05606042
Recruiting
Prospective, single arm, post-market evaluation to evaluate the use and performance of the IM Implant in a post market setting.
Gender:
ALL
Ages:
All
Trial Updated:
06/09/2023
Locations: Mount Carmel Research Institute, Columbus, Ohio
Conditions: Pelvic Ring Fracture, Acetabular Fracture, Pelvic Fracture, Pelvic Fracture Acetabulum
Register for Updates
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
NCT05291884
Recruiting
This is a prospective, multi-center, single-arm, early feasibility study that aims to evaluate the safety of the Impella BTR™ in adult patients requiring left-ventricular hemodynamic support, and to evaluate the effectiveness of the Impella BTR™ in supporting patients to recovery or their next therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/07/2023
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Heart Failure, Acute Decompensated Heart Failure
Register for Updates
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
NCT03797391
Recruiting
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2023
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Register for Updates
Biology of Juvenile Myoclonic Epilepsy
NCT03400371
Recruiting
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve pa... Read More
Gender:
ALL
Ages:
Between 10 years and 40 years
Trial Updated:
05/24/2023
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Juvenile Myoclonic Epilepsy
Register for Updates
Diagnostic POCUS of Patellar Tendinopathy in Female Athletes
NCT05880277
Recruiting
Purpose: The purpose of this study is to determine the clinical effectiveness of point-of-care diagnostic ultrasound in the assessment of patellar tendon pathologies
Gender:
FEMALE
Ages:
Between 18 years and 25 years
Trial Updated:
05/18/2023
Locations: Youngstown State University, Youngstown, Ohio
Conditions: Patellofemoral Disorder
Register for Updates
Electroencephalogram (EEG) Enhanced Transcranial Magnetic Stimulation (eTMS) for Chronic Trauma and Stressor-Related Disorders (TSRD)
NCT05835414
Recruiting
The goal of this clinical trial is to learn about the safety, feasibility, and preliminary efficacy of EEG-enhanced transcranial magnetic stimulation (eTMS) as an adjunct to standard-of-care therapies for chronic trauma and stressor related disorders (TSRD) among US military veterans. The main questions the study aims to answer are: * Is it safe to provide 30 sessions of eTMS for veterans with chronic TSRD? * Is it feasible to provide 30 sessions of eTMS as an adjunct to standard-of-care thera... Read More
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/03/2023
Locations: BEP Medical Group LLC, Columbus, Ohio
Conditions: Trauma and Stressor Related Disorders
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates